Explore

Trendline Trendline
FDA Launches Real-Time Clinical Trial Pilot with AstraZeneca and Amgen

FDA Launches Real-Time Clinical Trial Pilot with AstraZeneca and Amgen

FDA Launches Real-Time Clinical Trial Pilot with AstraZeneca and Amgen
Rapid Read Rapid Read
FDA Partners with Amgen and AstraZeneca for Real-Time Clinical Trials Using Cloud Technology

FDA Partners with Amgen and AstraZeneca for Real-Time Clinical Trials Using Cloud Technology

The FDA has launched an initiative to streamline drug development and review processes through real-time clinical trials, utilizing cloud technology. Amgen and AstraZeneca are participating in this pilot program, which allows FDA reviewers to access safety signals and clinical endpoints in real-time during trials. AstraZeneca will apply this system in its Phase 2 TRAVERSE study for mantle cell lymphoma, while Amgen will use it for the Phase 1b STREAM-SCLC study in small cell lung cancer. The FDA has successfully validated data from AstraZeneca's program, demonstrating the feasibility of real-time data sharing. The agency is also seeking public feedback on the framework's design and implementation.
Trendline Trendline
FDA Initiates AI-Driven Pilot to Expedite Clinical Trials for Cancer Drugs

FDA Initiates AI-Driven Pilot to Expedite Clinical Trials for Cancer Drugs

FDA Initiates AI-Driven Pilot to Expedite Clinical Trials for Cancer Drugs
Rapid Read Rapid Read
FDA Launches AI-Powered Real-Time Clinical Trial Initiative with AstraZeneca and Amgen

FDA Launches AI-Powered Real-Time Clinical Trial Initiative with AstraZeneca and Amgen

The FDA has announced a new initiative to utilize artificial intelligence (AI) in clinical trials, aiming to accelerate drug development by allowing real-time data reporting. AstraZeneca and Amgen are set to pilot this model, with two trials planned to report endpoints and data signals to the FDA as they occur. This approach seeks to address the traditional bottlenecks in drug development, characterized by high uncertainty and inefficient decision-making processes. FDA Commissioner Marty Makary, alongside the agency's first chief AI officer, Jeremy Walsh, emphasized the potential of this modern approach to transform clinical trials by enabling continuous data monitoring. The initiative includes a request for information (RFI) to gather feedback on the proposal, with comments open until May 29. The pilot studies involve AstraZeneca's phase 2 TrAVeRse trial and Amgen's phase 1b STREAM-SCLC trial, focusing on innovative cancer treatments.
Trendline Trendline
FDA Initiates AI-Driven Pilot to Accelerate Clinical Trials

FDA Initiates AI-Driven Pilot to Accelerate Clinical Trials

FDA Initiates AI-Driven Pilot to Accelerate Clinical Trials
Rapid Read Rapid Read
FDA Launches AI-Driven Pilot for Real-Time Clinical Trials to Expedite Drug Approvals

FDA Launches AI-Driven Pilot for Real-Time Clinical Trials to Expedite Drug Approvals

The Food and Drug Administration (FDA) has announced a groundbreaking pilot program that utilizes artificial intelligence (AI) and cloud computing to monitor clinical trial data in real time. This initiative aims to significantly reduce the time required for the approval of new drugs, devices, and medications. The pilot involves pharmaceutical companies AstraZeneca and Amgen, who will implement the system in their respective clinical trials. The FDA's Chief Artificial Intelligence Officer, Jeremy Walsh, emphasized that the program could potentially cut clinical trial timelines by up to 40%, without compromising safety. The FDA is also seeking public and industry input on how AI technologies can enhance efficiency and decision-making in early-phase clinical trials, with responses due by May 29.
Rapid Read Rapid Read
Paradigm Health and FDA Collaborate to Enhance Clinical Trial Review Process

Paradigm Health and FDA Collaborate to Enhance Clinical Trial Review Process

Paradigm Health has announced a collaboration with the U.S. Food & Drug Administration (FDA) to develop a new model for accelerating clinical trial execution and regulatory review. This initiative utilizes Paradigm Health's technology-enabled Study Conduct platform, which automates data collection and analysis, allowing for real-time review by the FDA. The collaboration aims to reduce the burden of monitoring, data entry, and trial costs, thereby speeding up regulatory review and improving the efficiency of U.S. clinical trials. The model is currently being tested in a Phase 2 trial sponsored by AstraZeneca and a Phase 1b trial sponsored by Amgen. The platform captures data from electronic health records and other sources, evaluates it algorithmically, and transmits only critical signals to the FDA and trial sponsors.
Trendline Trendline
FDA and Paradigm Health Collaborate to Modernize Clinical Trial Data Review

FDA and Paradigm Health Collaborate to Modernize Clinical Trial Data Review

FDA and Paradigm Health Collaborate to Modernize Clinical Trial Data Review
Trendline Trendline
FDA Accuses Amgen of Data Manipulation in Tavneos Approval, Raises Safety Concerns

FDA Accuses Amgen of Data Manipulation in Tavneos Approval, Raises Safety Concerns

FDA Accuses Amgen of Data Manipulation in Tavneos Approval, Raises Safety Concerns
Rapid Read Rapid Read
FDA Grants Priority Review for Gilead's New HIV Treatment, Potentially Transforming Care

FDA Grants Priority Review for Gilead's New HIV Treatment, Potentially Transforming Care

Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for a novel HIV treatment combining bictegravir and lenacapavir. This investigational, once-daily single-tablet regimen is designed for adults with virological suppression. The FDA has granted a priority review, setting a Prescription Drug User Fee Act (PDUFA) action date for August 27, 2026. The combination aims to provide sustained virologic suppression with a high barrier to resistance, particularly benefiting those with complex treatment histories or comorbidities. The NDA is supported by positive Phase 3 trial data, demonstrating efficacy in maintaining virological suppression and improving patient-reported treatment satisfaction.
Rapid Read Rapid Read
FDA Advisory Committee to Review AstraZeneca's Cancer Drug Applications Amid Concerns

FDA Advisory Committee to Review AstraZeneca's Cancer Drug Applications Amid Concerns

The FDA is set to hold its first drug-related advisory committee meeting in nine months to evaluate AstraZeneca's applications for two cancer drugs. The meeting will focus on the oral SERD drug camizestrant for HR-positive, HER2-negative breast cancer and the AKT inhibitor Truqap for metastatic hormone-sensitive prostate cancer. The FDA has raised questions about the clinical benefits and trial designs of these drugs, particularly regarding the validity of results and the timing of treatment interventions. The advisory panel will assess whether AstraZeneca has provided sufficient evidence to support the clinical benefits of these drugs.
Rapid Read Rapid Read
UK Implements Legislation to Expedite Clinical Trials, Enhancing Research Competitiveness

UK Implements Legislation to Expedite Clinical Trials, Enhancing Research Competitiveness

The UK government has enacted new legislation aimed at accelerating the approval process for clinical trials, marking the most significant reform in over two decades. Effective from April 28, 2026, the legislation allows researchers to apply simultaneously for ethics and regulatory approval for new clinical trials of investigational medicinal products. This reform, developed by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA), reduces the average approval time to 41 days, significantly less than previous durations. The initiative is part of the NHS's 'Fit for the Future' ten-year health plan, which aims to reduce clinical trial setup times to 150 days by March 2026. The legislation also introduces a 'risk-proportionate review' for certain trial modifications, further streamlining the process.